SG11202111679XA - Engineered cells and uses thereof - Google Patents
Engineered cells and uses thereofInfo
- Publication number
- SG11202111679XA SG11202111679XA SG11202111679XA SG11202111679XA SG11202111679XA SG 11202111679X A SG11202111679X A SG 11202111679XA SG 11202111679X A SG11202111679X A SG 11202111679XA SG 11202111679X A SG11202111679X A SG 11202111679XA SG 11202111679X A SG11202111679X A SG 11202111679XA
- Authority
- SG
- Singapore
- Prior art keywords
- engineered cells
- engineered
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083748 | 2019-04-22 | ||
| PCT/CN2020/086073 WO2020216238A1 (en) | 2019-04-22 | 2020-04-22 | Engineered cells and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111679XA true SG11202111679XA (en) | 2021-11-29 |
Family
ID=72940812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111679XA SG11202111679XA (en) | 2019-04-22 | 2020-04-22 | Engineered cells and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230144237A1 (en) |
| EP (1) | EP3959307A4 (en) |
| JP (1) | JP2022530211A (en) |
| CN (1) | CN113728095A (en) |
| AU (1) | AU2020261886A1 (en) |
| SG (1) | SG11202111679XA (en) |
| WO (1) | WO2020216238A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| WO2022171113A1 (en) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | Human cd33 antibody and use thereof |
| MX2023012902A (en) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame. |
| US20250082754A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Anti-cd33 antibodies and uses thereof |
| US20250082681A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Antibodies against cll1 and constructs thereof |
| CN116024175A (en) * | 2021-10-27 | 2023-04-28 | 南京北恒生物科技有限公司 | Engineered immune cells and uses thereof |
| CN114807237A (en) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | Preparation method and application of NK (natural killer) cells for over-expressing CD16a |
| CN116574748B (en) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | A construction method of chimeric nTCR-T for targeting KRAS high-frequency mutated tumors |
| CN118891290A (en) * | 2024-04-12 | 2024-11-01 | 科济生物医药(上海)有限公司 | Compositions and methods for cellular immunotherapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013126726A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| CA3115383A1 (en) * | 2013-02-06 | 2014-08-14 | Celgene Corporation | Modified t lymphocytes having improved specificity |
| WO2015063069A1 (en) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN105384825B (en) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
| US11549099B2 (en) * | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CN109715668A (en) * | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | For using fusion protein to carry out the composition and method of TCR reprogramming |
| CA3044593A1 (en) * | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR20250072712A (en) * | 2016-12-02 | 2025-05-26 | 앤젤레스 테라퓨틱스, 인코포레이티드 | Synthetic immune receptors and methods of use thereof |
| CN109593721B (en) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技(上海)有限公司 | Engineered immune cells targeting human mesothelin with suicide gene switch |
-
2020
- 2020-04-22 SG SG11202111679XA patent/SG11202111679XA/en unknown
- 2020-04-22 WO PCT/CN2020/086073 patent/WO2020216238A1/en not_active Ceased
- 2020-04-22 JP JP2021562388A patent/JP2022530211A/en active Pending
- 2020-04-22 US US17/605,290 patent/US20230144237A1/en not_active Abandoned
- 2020-04-22 CN CN202080029628.8A patent/CN113728095A/en active Pending
- 2020-04-22 EP EP20794972.8A patent/EP3959307A4/en not_active Withdrawn
- 2020-04-22 AU AU2020261886A patent/AU2020261886A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020216238A1 (en) | 2020-10-29 |
| US20230144237A1 (en) | 2023-05-11 |
| EP3959307A4 (en) | 2023-08-23 |
| JP2022530211A (en) | 2022-06-28 |
| AU2020261886A1 (en) | 2021-11-18 |
| EP3959307A1 (en) | 2022-03-02 |
| CN113728095A (en) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277673A (en) | Engineered cells and uses thereof | |
| IL288738A (en) | Engineered casx systems and uses thereof | |
| SG11202111679XA (en) | Engineered cells and uses thereof | |
| IL277611A (en) | Engineered immune effector cells and use thereof | |
| EP3964238A4 (en) | Bcma-targeting engineered immune cell and use thereof | |
| SG11202101994XA (en) | Genetically engineered hematopoietic stem cells and uses thereof | |
| SG11202101204TA (en) | Processes for generating engineered cells and compositions thereof | |
| SG11202111973RA (en) | Engineered t cells | |
| IL282092B (en) | Engineered enzymes | |
| IL274505A (en) | Novel engineered t cell receptors and immune therapy using the same | |
| IL287874A (en) | T cell manufacturing compositions and methods | |
| SG11202011392VA (en) | Genetically engineered cell and application thereof | |
| PL3414787T3 (en) | Pre-lithiated electrode materials and cells employing the same | |
| IL281171A (en) | Cellulose-synthase-like enzymes and uses thereof | |
| SG11202107269XA (en) | Modified cell expansion and uses thereof | |
| IL290109A (en) | Cells for improved immunotherapy and uses thereof | |
| IL287503A (en) | Thiosemicarbazates and uses thereof | |
| IL273247A (en) | Novel cell line and uses thereof | |
| GB2603882B (en) | Cell unit and cell stack | |
| GB201914611D0 (en) | Engineered immune cell | |
| IL283757A (en) | Engineered flagellin-derived compositions and uses | |
| SG11202108740UA (en) | Engineered immune cells | |
| SG11202105217RA (en) | Placenta-derived allogeneic car-t cells and uses thereof | |
| SG10201909544YA (en) | Genetically Modified T Cells And Uses Thereof | |
| GB201915526D0 (en) | Modified cell |